Recent Updates
Recently added Catalysts
JNJ Positive Sentiment

Johnson & Johnson’s Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September

Tuesday, August 4, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Johnson & Johnson has announced the retirement of Jennifer Taubert, Executive Vice President and Worldwide Chairman of Innovative Medicine, after a notable 21-year career. Under her leadership, the Innovative Medicine sector achieved over $60 billion in annual revenue. Tom Cavanaugh has been appointed as her successor, effective September.

Market Sentiment Analysis

POSITIVE FACTORS

  • Jennifer Taubert had a distinguished career at Johnson & Johnson.
  • The Innovative Medicine business grew to over $60 billion in revenue.
  • Tom Cavanaugh's appointment signals continuity in leadership.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.6%
average across 15 past catalysts
Lead asset
Tapentadol
Phase 3 · Osteoarthritis, Hip

Full Press Release Details

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that Jennifer Taubert will retire from her position as Executive Vice President, Worldwide Chairman, Innovative Medicine following a distinguished career and over 21-year tenure at Johnson & Johnson. Under her leadership, the Company’s Innovative Medicine business grew to more than $60 billion in annual revenue and strengthened its position as one of the most respected and successful pharmaceutical busin

Frequently Asked Questions

Who is retiring from Johnson & Johnson?

Jennifer Taubert is retiring from her position at Johnson & Johnson.

What position did Jennifer Taubert hold?

She was the Executive Vice President and Worldwide Chairman of Innovative Medicine.

Who is replacing Jennifer Taubert?

Tom Cavanaugh has been appointed as her successor.

How long did Jennifer Taubert work at J&J?

She had a distinguished career spanning over 21 years.

What revenue did the Innovative Medicine business achieve?

The business grew to more than $60 billion in annual revenue.

ShareAdd on Google
Tags: JNJ Viatris Investor Conferences Healthcare Johnson & Johnson Jennifer Taubert Tom Cavanaugh Innovative Medicine pharmaceutical
Last updated: Aug 4, 2026

Biotech snapshot

Cash runway
$20758M liquidity · $0M/mo burn
Low dilution risk
Lead asset
TapentadolPhase 3
Osteoarthritis, Hip →

Catalyst track record

+34%
best trade around JNJ's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for JNJ.

See every catalyst's timing & PoA →